Is Collegium Pharmaceutical, Inc. (COLL) a Buy, Sell, or Hold?
NASDAQ : COLL
Collegium Pharmaceutical, Inc.
$36.08 USD
-$0.19 (-0.52%)
- Volume
- 311.95K
- Average Volume
- 439K
- Market Capitalization
- $1.17B
- P/E Ratio
- 15.22
- Dividend Yield
- 0.00%
- Price Target
- $58.00
- Year High
- $50.79
- Year Low
- $29.19
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.71
Company Overview
NASDAQ
Vikram Karnani
Drug Manufacturers - Specialty & Generic
Healthcare
COLL
423
US
USD
Liquidity Metrics
2.59
1.71
1.62
0.62
0.00
Sales & Valuation
$780.57M
1.47
3.71
3.55
10.28
Profitability
$1.73
$62.87M
9.41%
13.59%
26.74%
4.54%
P/E Metrics
15.22
0.22
0.22
Analyst Price Target & Rating
$58.00
$58.00
$58.00
3/5
12 Analysts
-37.79%
Poll Results
About Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc ... ., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
2026-07-09 10:41:39
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
2026-07-08 09:26:10
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
New Strong Buy Stocks for July 6th
2026-07-06 05:36:06
BBCP, KUBTY, ADM, COLL and W have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2026.
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
2026-07-01 11:45:48
COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
2026-06-23 10:40:46
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-05 08:00:00
STOUGHTON, Mass. , June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan (the 2026 Inducement Plan). The Company granted 50,305 restricted stock units (RSUs), in aggregate, as a material inducement to the employment of 34 non-executive individuals newly hired by the Company.
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-05 08:00:00
STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan (the 2026 Inducement Plan).
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
2026-05-27 08:00:00
STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.
Frequently Asked Questions
-
What is the current Collegium Pharmaceutical, Inc. (COLL) stock price?
-
Collegium Pharmaceutical, Inc.(NASDAQ:COLL) stock price is $36.08 in the last trading session. During the trading session, COLL stock reached the peak price of $50.787 while $29.19 was the lowest point it dropped to. The percentage change in COLL stock occurred in the recent session was --0.52% while the dollar amount for the price change in COLL stock was -$0.19.
-
COLL's industry and sector of operation?
-
The NASDAQ listed COLL is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of COLL?
-
Dean J. Patras | Chief People Officer
Thomas Smith FAAFP | Executive Vice President & Chief Medical Officer
Ian Karp | Head of Investor Relations
Scott Sudduth | EVP & Head of Technical Operations
Jane Gonnerman | Executive Vice President of Strategy & Corporate Development -
How many employees does COLL have?
-
Number of COLL employees currently stands at 423. COLL operates from 100 Technology Center Drive, Stoughton, MA 02072, US.
-
Link for COLL official website?
-
Official Website of COLL is: https://www.collegiumpharma.com
-
How do I contact COLL?
-
COLL could be contacted at phone #781 713 3699 and can also be accessed through its website. COLL operates from 100 Technology Center Drive, Stoughton, MA 02072, US.
-
How many shares of COLL are traded daily?
-
The average number of COLL shares traded daily for last 3 months was 439K.
-
What is the market cap of COLL currently?
-
The market value of COLL currently stands at $1.17B with its latest stock price at $36.08